Both are chains of amino acids joined by amide bonds. There is no chemical event at any particular length that converts one into the other, and anyone offering a precise cutoff is reporting a convention rather than a fact.
The convention most often used is around 50 residues, with shorter chains called peptides and longer ones proteins. It is a reasonable working line and it is worth understanding what it approximates.
The real distinction is folding
What actually separates the two categories is whether the chain adopts a stable, defined three-dimensional structure. A protein folds into a specific conformation, and that conformation is what gives it function; denature it and the function is lost even though every bond in the sequence is intact.
Most short peptides do not have a single stable fold. They are flexible in solution, sampling many conformations, and their activity generally depends on the sequence presenting a motif to a receptor rather than on a maintained global structure.
The 50-residue convention is a proxy for this, because chains much shorter than that rarely have enough interactions to hold a stable tertiary structure. Like all proxies it has exceptions in both directions: some short sequences are conformationally constrained, particularly cyclic ones or those held by a disulfide bond, and some long chains are intrinsically disordered.
| Peptide | Protein | |
|---|---|---|
| Conventional length | Under about 50 residues | Above about 50 residues |
| Structure | Usually no stable fold | A specific folded conformation |
| What activity depends on | Sequence and modifications | The fold being intact |
| Main failure mode | Chemical change to residues | Loss of conformation |
| Characterised by | Mass and sequence | Mass, sequence and higher-order structure |
| Handling consequence | Chemistry of the chain governs | Anything that unfolds it governs |
The residue count is a convention. Folding is the property that actually changes how material behaves.
What changes in practice
- Manufacture. Peptides are made by solid-phase synthesis, chemically, residue by residue. Proteins are generally produced by expression in a biological system, because stepwise synthesis of hundreds of residues is impractical and because the chain usually needs to fold correctly.
- What purity means. For a synthetic peptide, purity is a chemical question about what molecules are present. For a protein, a correctly sequenced but misfolded molecule is chemically correct and functionally useless, so potency or activity assays matter alongside chemical purity.
- Stability. Denaturation is a protein failure mode and barely a peptide one. A flexible short chain has no fold to lose, which is part of why peptides tolerate conditions that would destroy a protein.
- Analysis. Intact-mass measurement is straightforward on a peptide. Larger proteins often need enzymatic digestion and peptide mapping, because the intact mass of a large molecule is less informative.
Where catalog items sit
Almost everything in a research peptide catalog is comfortably on the peptide side, from three-residue GHK to the 39-residue incretin compounds. The items that sit near the boundary are the ones worth noting, such as thymosin beta-4 at 43 residues, which is often called a protein in the literature and a peptide in catalogs.
That ambiguity is not a labelling error so much as a demonstration that the line is a convention. For practical purposes, the question that matters is not which word applies but whether the molecule has a fold its function depends on, because that determines what the analysis needs to prove.
All material is supplied strictly for laboratory research.
Why the line matters for documentation
Because the characterisation that counts as complete differs. For a short peptide, mass and sequence largely settle what the material is. For a folded protein, mass and sequence leave the most important property unaddressed, since activity depends on a conformation that neither measures.
A certificate reporting identity and purity for something genuinely protein-sized is therefore answering a narrower question than the same certificate for a short peptide, and it is worth knowing which situation you are in.
Where catalogue items sit in practice
Most of a research peptide catalogue is comfortably on the peptide side, short enough that no stable fold is expected and chemistry governs behaviour. A few items sit near or above the conventional boundary, and those are the ones where handling advice written for short peptides transfers least well.
Reading peptide nomenclature covers reading length and modification from a name, which is usually enough to tell which side of the line something sits on.
Why the boundary moves
Because it is a convention rather than a chemical event, different fields place it in different places and the same molecule can be described either way depending on who is writing. Around fifty residues is the figure most often used, and it approximates the length at which a chain can begin to hold a stable fold.
The approximation is rough in both directions. Some short sequences adopt defined structure, and some longer chains remain disordered. Reading the convention as a measurement is the error worth avoiding.
What this changes for storage
For an unstructured peptide the threats are chemical: hydrolysis, oxidation and the other routes that alter residues. For a folded protein, anything that unfolds it is a threat even when no chemistry has occurred, which brings temperature, interfaces and agitation into play in a way they are not for a short chain.
That is why handling advice does not transfer cleanly across the boundary, and why the first useful question about any item is which side of it the material sits on.
For where this sits among the other molecules a catalogue carries, not everything in a peptide catalog is a peptide covers how the classes differ.